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PHeart Failure
Clinical Outcomes According to Baseline Blood
Pressure in Patients With a Low Ejection Fraction
in the CHARM (Candesartan in Heart failure: Assessment
of Reduction in Mortality and morbidity) Program
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Christopher B. Granger, MD,# Salim Yusuf, MB, BS, DPHIL,** Karl Swedberg, MD, PHD,††
Marc A. Pfeffer, MD, PHD, John J. V. McMurray, MD*
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Objectives This study sought to investigate the efficacy and tolerability of candesartan, according to baseline blood pres-
sure (BP), in the 4,576 patients with a low ejection fraction (EF) (0.40) in the CHARM (Candesartan in Heart
failure: Assessment of Reduction in Mortality and morbidity) program.
Background Hypotension is a predictor of poor prognosis in heart failure, yet many treatments shown to reduce morbidity
and mortality lower blood pressure. This paradox creates a dilemma for physicians and may explain why low BP
is reported as a reason for under-use of these agents.
Methods The interaction between treatment and baseline systolic blood pressure (SBP) and diastolic blood pressure
(DBP) was examined with patients divided into 6 SBP categories (100, 101 to 110, 111 to 120, 121 to 130,
131 to 140 and 141 mm Hg) and 4 DBP categories (60, 61 to 70, 71 to 80 and 81 mm Hg).
Results Low SBP and DBP were associated with worse clinical outcomes. Baseline BP did not modify the effects of can-
desartan on clinical outcomes: the interaction p value between SBP category and treatment was 0.38 (0.22 for
DBP category). For both placebo and candesartan, study drug discontinuation for adverse effects (especially hy-
potension) was highest in patients in the lowest baseline BP categories. However, the relative risk of discontinu-
ation for hypotension, renal dysfunction, and hyperkalemia in the candesartan compared with placebo group
was not increased in patients with a low baseline BP.
Conclusions In patients with low EF heart failure, the relative risks and benefits of candesartan treatment were similar in pa-
tients with a low BP compared to those with a higher BP. (J Am Coll Cardiol 2008;52:2000–7) © 2008 by the
American College of Cardiology Foundation










Pypotension is a recognized predictor of poor prognosis
n patients with heart failure (HF), yet many of the
reatments shown to reduce morbidity and mortality also
ower blood pressure (BP) (1– 4). This paradox presents a
ilemma to physicians when treating patients (5). Indeed,
his dilemma may explain why, in surveys of physician
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he use of agents known to improve outcome in HF (or a
eason for withdrawal of these treatments) (6,7). This is
rue for both angiotensin-converting enzyme (ACE)
nhibitors and beta-blockers, the combination of which is
ow the cornerstone of treatment of patients with HF
nd a low left ventricular ejection fraction (EF) (8 –10).
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2001JACC Vol. 52, No. 24, 2008 Meredith et al.
December 9, 2008:2000–7 Candesartan, BP, and HFhe issue of hypotension has been highlighted further by
he recent recommendation of angiotensin receptor
lockers as a third add-on treatment in patients with a
ow EF who remain symptomatic despite therapy with an
CE inhibitor and beta-blocker (8 –10).
To investigate the efficacy and tolerability of candesar-
an, according to baseline BP, we analyzed the 2 low EF
0.40) trials in the CHARM (Candesartan in Heart
ailure: Assessment of Reduction in Mortality and mor-
idity) program (11–14).
ethods
he CHARM program. The design, baseline findings,
nd primary results of the CHARM program have been
eported in detail (11–15). Briefly, it consisted of 3 inde-
endent but related trials in which patients with New York
eart Association (NYHA) functional class II to IV HF
ere randomized to candesartan (force titrated over 6 to 8
eeks to a target dose of 32 mg once daily, as tolerated) or
atching placebo. Patients were enrolled into the individual
HARM trials according to EF and treatment with an
CE inhibitor.
Patients with an EF 0.40 who were intolerant of an
CE inhibitor were enrolled in the CHARM-
lternative trial, whereas patients with an EF 0.40 and
aking an ACE inhibitor were enrolled in the CHARM-
dded trial. In this component trial, patients in NYHA
unctional class II must have had a hospital admission for
cardiac reason in the previous 6 months (this had the
ffect of increasing the proportion of NYHA functional
lass III/IV patients in the CHARM-Added trial). In-
estigators were also encouraged to use evidence-based
oses of ACE inhibitors in patients randomized to the
HARM-Added trial.
Patients with an EF 0.40 were randomized into
HARM-Preserved trial, which was not considered further
n this analysis because candesartan did not improve the
rimary outcome in this component trial and candesartan is
ot approved for the treatment of HF with a preserved EF.
There was no specific lower BP exclusion criterion,
lthough patients with current symptomatic hypotension
ould not be randomized. Patients with a serum creatinine
3 mg/dl (265 mol/l) were excluded. Patients with a
erum potassium5.5 mmol/l (or a history of marked ACE
nhibitor–induced hyperkalemia resulting in a serum potas-
ium 6.0 mmol/l or a life-threatening adverse event) also
ere excluded.
The CHARM program was completed, as planned, 2
ears after the last patient was randomized. Because the rate
f recruitment varied between the component CHARM
rials, the median follow-up time was 41 months in the
HARM-Added trial and 34 months in the CHARM-
lternative trial (40 months in the 2 low-EF CHARMrials combined). dThe primary outcome for each
f the component trials was the
omposite of death from a cardio-
ascular (CV) cause or unplanned
dmission to the hospital for the
anagement of worsening HF,
nd in the overall CHARM pro-
ram, death from any cause (which
as also a pre-specified outcome
n the planned analysis of the 2
ow-EF trials combined). At each
ollow-up visit, investigators were
sked whether the study drug had
een discontinued because of:
ymptomatic or severe hypoten-
ion, abnormal renal function, or
yperkalemia (or other reasons).
aseline BP categories. The CHARM pre-specified anal-
sis plan stated that outcomes according to randomized
reatment allocation would be analyzed according to the
ollowing systolic blood pressure (SBP) categories: 100
nd 100 mm Hg and 140 and 140 mm Hg; and the
ollowing diastolic blood pressure (DBP) categories: 70
nd70 mm Hg and90 and90 mm Hg. Subsequently,
owever, we decided that a more extensive analysis would be
ore valuable. Consequently, for this retrospective analysis,
atients were divided into 6 clinically relevant SBP catego-
ies: 100, 101 to 110, 111 to 120, 121 to 130, 131 to 140
nd 141 mm Hg. The following 4 DBP categories were
nalyzed: 60, 61 to 70, 71 to 80, and 81 mm Hg.
tatistical analysis. Summary statistics of an extensive list
f baseline characteristics including demographics, history
nd etiology of HF, comorbidity, body mass index, vital
igns, clinical signs and symptoms of HF, electrocardio-
raphic findings, and HF medications were analyzed ac-
ording to baseline SBP and DBP at randomization. The
ox proportional-hazards model was used to estimate the
azard ratio for the effect of treatment in each BP group as
ell as to calculate the p value for the interaction between
reatment effect and BP group on each end point (CV death
r HF hospitalization and all-cause death).
The same model was used to analyze the time to
iscontinuation of study drug (because of hypotension, renal
ysfunction, or hyperkalemia).
esults
aseline characteristics. There were 4,576 patients with
n EF 0.40 randomized in the CHARM program. The
aseline characteristics according to SBP are shown in
able 1. Patients with a lower SBP were younger and had a
orse NYHA functional class status, a lower median EF,
nd a greater prevalence of coronary heart disease and
istory of atrial fibrillation, but less hypertension. Patients





BP  blood pressure
CV  cardiovascular
DBP  diastolic blood
pressure
EF  ejection fraction (left
ventricular)
HF  heart failure
NYHA  New York Heart
Association
SBP  systolic blood
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Candesartan, BP, and HF December 9, 2008:2000–7reated with a calcium-channel blocker. Similar trends were
oted when the DBP categories were analyzed and when
he CHARM-Alternative and the CHARM-Added trials
ere analyzed separately.
ose of candesartan and placebo achieved. The median
range) dose of both candesartan and placebo taken by
atients still receiving treatment at the end of titration
eriod was 8 mg (range 4 to 16 mg) in subjects with a
aseline SBP 100 mm Hg and 16 mg (range 8 to 16 mg)
atient Characteristics According to Baseline Blood Pressure






Mean (SD) age (yrs) 63 (11) 63 (
Age 75 yrs (%) 15 17
Male (%) 80 76




Median LV ejection fraction 0.25 0
Mean (SD) heart rate (beats/min) 74 (5) 74 (
Mean (SD) blood pressure (mm Hg)
Systolic 96 (5) 108 (






Hospital admission for HF 79 75
Myocardial infarction 61 62
Current angina 18 21
Stroke 8 7
Diabetes mellitus 28 24
Hypertension 26 36
Atrial fibrillation 30 28
Pacemaker 14 10
Percutaneous coronary intervention 16 18
Coronary artery bypass grafting 24 26
Implantable cardioverter-defibrillator 9 6
Medical treatment (%)






Oral anticoagulant 49 42
Antiarrhythmic agent (including amiodarone) 1 2
Lipid-lowering drug 43 43
Long-acting nitrate 32 33
Calcium-channel blocker 6 9
Other vasodilators (including hydralazine) 7 5
CE  angiotensin-converting enzyme; HF  heart failure; IQR  interquartile range; LV  left veor both treatments in patients with an SBP 101 to 110 em Hg. For all other SBP groups, the dose of placebo was
6 mg (range 16 to 16 mg). For candesartan it was 16 mg
range 8 to 16 mg) in those with an SBP 111 to 140 mm Hg
nd 16 mg (range 16 to 16 mg) in those with an SBP 140
m Hg. Similar trends were noted when the DBP catego-
ies were analyzed and when the CHARM-Alternative and
HARM-Added trials were analyzed separately (data not
hown).











64 (11) 65 (10) 66 (11) 68 (10)
18 18 25 27
77 74 74 68
31 35 37 39
66 63 61 59
3 2 3 2
0.29 0.3 0.31 0.31
74 (13) 73 (12) 74 (14) 74 (13)
118 (3) 128 (3) 138 (3) 155 (9)
74 (8) 77 (9) 80 (9) 85 (10)
68 64 65 61
4 7 8 13
23 24 21 21
71 74 72 72
62 58 58 52
22 21 23 22
8 9 9 10
29 32 27 30
41 52 52 71
26 27 23 26
10 10 6 7
16 16 15 13
26 24 23 25
3 3 2 2
60 56 50 47
56 54 53 52
22 19 16 13
87 87 87 86
55 51 49 49
55 53 57 59
36 34 29 27
2 2 2 2
42 41 40 40
35 35 37 34
12 13 14 21
6 34 7 6
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December 9, 2008:2000–7 Candesartan, BP, and HFable 2. BP increased in the patients with the lowest
tarting value and decreased the most in those with a higher
aseline pressure. BP increased less in the candesartan-
reated patients (compared with placebo-treated patients) in
he lower BP groups and decreased more with candesartan
n the higher BP groups. There was, however, no evidence
f a systematic difference in the placebo-corrected response
o candesartan in the different BP groups.
linical outcomes CV death or HF hospitalization. Pa-
ients with a low SBP (or DBP, data not shown) at baseline
ad a greater risk of CV death or HF hospitalization than
hose with a higher BP (Fig. 1 and Table 3). This risk
ncreased sharply at an SBP below 110 mm Hg, and
specially below 100 mm Hg. Baseline SBP and DBP did
ot modify the effect of candesartan on this composite
utcome (Fig. 2 and Table 3). The interaction p value
etween SBP (categories) and treatment was 0.38 (Fig. 2A).
he interaction p value between DBP (categories) and
reatment was 0.22 (Fig. 2B). These findings were similar
hen the CHARM-Alternative and -Added trials were
nalyzed individually (data not shown).
ll-cause mortality. Similarly, patients with a low SBP (or
BP at baseline, data not shown) had a greater risk of death
rom any cause than those with a higher BP (Table 3).
aseline SBP and DBP did not modify the effect of
andesartan on this outcome (Fig. 3 and Table 3). The
nteraction p value between SBP (categories) and treatment
as 0.85 (Fig. 3A). The interaction p value between DBP
categories) and treatment was 0.76 (Fig. 3B). These find-
ngs were similar when the CHARM-Alternative and
Added trials were analyzed individually (data not shown).
olerability and safety. The proportion of patients that
iscontinued the study drug for hypotension, renal dysfunc-
ion, and hyperkalemia in each SBP category is shown in
able 4. Patients in the lowest SBP category had the highest
lacebo-group rate of discontinuation for each of these
dverse effects. Generally, patients treated with candesartan
ad an increased rate of discontinuation for each of these
dverse effects compared with patients treated with placebo,
lthough the increased risk was most apparent for hyperka-
emia. The risk of discontinuation because of hypotension in
oth the placebo and the candesartan groups increased
arkedly when the baseline SBP was 110 mm Hg. For
ean (SD) Change in SBP From Baselineo E d of Forced Titration in Each SBP Category





100 8.3 (13.4) 4.6 (14.6)
101 to 110 4.0 (14.2) 0.1 (14.0)
111 to 120 0.8 (14.1) 4.9 (14.9)
121 to 130 1.8 (14.7) 8.3 (16.0)
131 to 140 6.6 (15.4) 11.4 (17.3)
140 13.1 (17.7) 16.6 (19.1)o
HARM Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity trials;
F  ejection fraction; SBP  systolic blood pressure.atients in the lowest SBP category, the greatest relative
ncrease in risk for discontinuation with candesartan was for
ypotension, with no evidence of increased risk of hyper-
alemia or renal dysfunction. Similar findings were noted
hen the DBP categories were examined and when the
HARM-Alternative and -Added trials were analyzed
ndividually (data not shown).
iscussion
he principal findings of this analysis of the CHARM
ow-EF trials were that a low SBP (and a low DBP) was
ssociated with worse clinical outcomes and that baseline
P did not modify the effects of candesartan on clinical
utcomes.
These findings are important because practicing physi-
ians often are concerned about giving additional treatment
ith a hypotensive action to HF patients with a low BP (7).
ur analyses show that this can be done with a low
ncidence of adverse effects and anticipation of as much
linical benefit as in patients with a higher BP. Further-
ore, the incremental risk of adverse effects with candesar-
an, compared with placebo, was not greater in patients with
low baseline BP compared with those with a higher BP at
rial entry.
Our findings are in keeping with those of the A-HeFT
African-American Heart Failure Trial) study, in which the
ffects of adding the combination of hydralazine and isosor-
ide dinitrate to conventional therapy were consistent above
n  513) and below (n  537) the median SBP of 126
m Hg. Despite the findings of the A-HeFT study, however,
here was still uncertainty about the use of drugs with a
ypotensive action in patients with a very low SBP, because in
hat study only 229 patients had an SBP 112 mm Hg and
Figure 1
Risk of CV Death or HF Hospitalization
According to Baseline SBP in the Randomized
Placebo and Candesartan Treatment Groups
CV  cardiovascular; HF  heart failure; SBP  systolic blood pressure.nly 79 had an SBP 100 mm Hg (4). By contrast, the
CI  confidence interval; HR  hazard ratio; LVEF  left ventricular ejection fraction; other abbreviations as in Table 2.
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Candesartan, BP, and HF December 9, 2008:2000–7Figure 2 Effect of Candesartan on Primary Composite Outcome According to Baseline Blood Pressure
(A) Effect of candesartan compared with placebo on the risk of cardiovascular death or heart failure hospitalization according to baseline systolic blood pressure (SBP). (B) Effect ofPre-Specified Composite Mortality/Morbidity Outcomeand All-Cause Death in the CHARM L w LVEF Trials According to Baseline SBP
Table 3 Pre-Specified Composite Mortality/Morbidity Outcomeand All-Cause Death in the CHARM Low LVEF Trials According to Baseline SBP
Events Per 1,000 Years
Follow-Up
p for
InteractionCandesartan Placebo HR (95% CI)
Cardiovascular death or heart failure hospitalization
SBP 100 mm Hg (n  385) 228 251 0.90 (0.68–1.19)
SBP 101 to 110 mm Hg (n  698) 156 197 0.80 (0.63–1.00)
SBP 111 to 120 mm Hg (n  910) 136 162 0.85 (0.69–1.06) 0.38
SBP 121 to 130 mm Hg (n  908) 154 169 0.91 (0.74–1.12)
SBP 131 to 140 mm Hg (n  751) 110 148 0.58 (0.58–0.96)
SBP 141 mm Hg (n  924) 110 165 0.54 (0.54–0.85)
All patients (n  2,548) 140 173 0.82 (0.74–0.90)
All-cause death
SBP 100 mm Hg (n  385) 154 153 0.98 (0.71–1.36)
SBP 101 to 110 mm Hg (n  698) 108 127 0.85 (0.65–1.10) 0.85
SBP 111 to 120 mm Hg (n  910) 96 122 0.79 (0.62–1.00)
SBP 121 to 130 mm Hg (n  908) 101 107 0.94 (0.74–1.20)
SBP 131 to 140 mm Hg (n  751) 84 101 0.84 (0.64–1.12)
SBP 141 mm Hg (n  924) 82 93 0.88 (0.68–1.15)
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December 9, 2008:2000–7 Candesartan, BP, and HFHARM low-EF trials included almost 2,000 patients with
n SBP 120 mm Hg and 385 with an SBP 100 mm Hg.
In the same way, our findings also support and extend
hose of an analysis of the COPERNICUS (Carvedilol
rospective Randomized Cumulative Survival) study, in
Figure 3 Effect of Candesartan on All-Cause Mortality Accordin
(A) Effect of candesartan compared with placebo on the risk of all-cause mortality
of candesartan compared with placebo on the risk of all-cause mortality according
easons for Permanent Discontinuation of Study DrugR te Per 1,000 Patient Years of Foll w-Up) According to Baseline
Table 4 Reasons for Permanent Discontinuation of Study Drug(Rate Per 1,000 Patient Years of Follow-Up) According
D
Hypotension
Candesartan Placebo HR (95% CI) Candesar
SBP 100 mm Hg 43.4 13.7 3.16 (1.28–7.81) 23.1
SBP 101 to 110
mm Hg
26.4 16.0 1.68 (0.88–3.21) 32.1
SBP 111 to 120
mm Hg
12.7 9.5 1.35 (0.64–2.86) 24.1
SBP 121 to 130
mm Hg
11.6 6.5 1.81 (0.77–4.27) 26.7
SBP 131 to 140
mm Hg
10.3 3.8 2.75 (0.87–8.63) 24.8
SBP 141 mm Hg 5.3 3.1 1.84 (0.54–6.29) 24.4andesartan/placebo HRs with 95% CIs are also given.
Abbreviations as in Tables 2 and 3.hich the benefits of the beta- and alpha-adrenergic recep-
or blocking agent used were consistent across the SBP
ategories examined (1). In that analysis, 264 patients had
n SBP in the range of 105 to 96 mm Hg and 132 in the
ange of 95 to 85 mmHg.
Baseline Blood Pressure
ding to baseline SBP. (B) Effect
eline DBP. Abbreviations as in Figure 2.
aseline SBP
inuation of Study Drug
nal Dysfunction Hyperkalemia
Placebo HR (95% CI) Candesartan Placebo HR (95% CI)
22.9 1.01 (0.44–2.33) 3.7 4.5 0.82 (0.12–5.85)
15.9 2.03 (1.09–3.79) 9.6 1.0 9.37 (1.19–73.95)
13.5 1.79 (0.99–3.24) 7.1 0.8 9.15 (1.16–72.20)
8.1 3.28 (1.62–6.64) 12.4 2.4 5.08 (1.48–17.45)
11.4 2.17 (1.10–4.31) 13.2 1.9 6.91 (1.57–30.39)
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Candesartan, BP, and HF December 9, 2008:2000–7We found that BP decreased with both placebo and
andesartan in the higher baseline BP categories. In con-
rast, the groups with a baseline SBP 100 mm Hg had an
ncrease in BP after randomization, although the increase
as smaller in the candesartan group. This finding is
onsistent with both the A-HeFT study and the COPER-
ICUS study, in which BP increased in those in the lowest
aseline BP categories in both the placebo and active
herapy groups (1,4). Although this pattern of BP change
uggests regression to the mean, the considerably higher risk
f clinical events in those with the lowest baseline BP
ndicates that the recorded baseline BP was of biologic
mportance.
Patients with the lowest baseline BP were less likely to be
itrated to higher doses of study drug, but this was true of
oth placebo- and candesartan-treated patients. We also
ound that hypotension, reported as the cause of discontin-
ation of study drug, was more common in patients in the
lowest baseline BP categories, irrespective of treatment
llocation. Overall, patients treated with candesartan were
ore likely to stop treatment because of hypotension than
hose treated with placebo. Although the highest absolute
ate of treatment discontinuation for hypotension was in
atients in the lowest SBP category at baseline treated with
andesartan, the incremental risk with candesartan, com-
ared with placebo, was not greater in these highest-risk
atients in the lowest baseline BP category. Importantly, the
ajority of patients with a low BP at baseline remained on
tudy drug and obtained similar benefits. These findings are
lso consistent with the results of the A-HeFT and CO-
ERNICUS trials (1,4). Collectively, these studies show
hat HF patients with a low SBP are at greater risk of
dverse clinical outcomes, are less likely to achieve target
oses of evidence-based therapy, are no more likely in
elative terms to discontinue such treatment, and in absolute
erms, obtain as much or greater benefit from these treat-
ents.
It was also noteworthy that there was no excess risk
elated to candesartan of renal dysfunction or hyperkalemia
n patients with a low baseline BP, although study drug
iscontinuation for both of these adverse effects was more
ommon overall in the candesartan group compared with
he placebo group and more common in patients with a low
aseline BP, irrespective of treatment group, than in those
ith a higher BP.
Our analyses have some limitations. They are retrospec-
ive, and although larger than in prior studies, the number
f patients in the lowest SBP group at baseline is still
elatively small.
linical implications. In summary, a low SBP should
ot deter physicians from prescribing evidence-based
herapy with a hypotensive action, although such treat-
ent should, of course, be used cautiously and withppropriate monitoring of patients for tissue underperfu-ion, for example, causing pre-syncope/syncope or wors-
ning renal function.
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